(BW)(GA-HEALTH-DISCOVERY)(HDVY) Health Discovery Corporation针对新的前列腺癌生物标记发现提交美国及国外专利保护相关文件

新的前列腺癌生物标记表达谱在鉴定前列腺癌方面具有很高的精确性

美国商业资讯2007年2月5日佐治亚州SAVANNAH消息——

Health Discovery Corporation（HDC）（场外柜台交易市场代码：HDVY）今天宣布，已针对最新发现的前列腺癌生物标记表达谱的美国及国外专利保护，向美国专利商标局（United States Patent and Trademark Office）和负责专利合作协议的美国接收处（U.S. Receiving Office）提交了新的专利应用。最新发现的前列腺癌生物标记表达谱可以非常准确地鉴定前列腺癌。这项新的前列腺癌生物标记表达谱业已被证明具有很高的精度，经计算ROC曲线下面积可达94%。

HDC公司科学团队主席、德克萨斯州大学安德森癌症中心（University of Texas M.D. Anderson Cancer Center）医学实验室教授Herbert A. Fritsche博士评价说：“这个新的令人激动的生物标记发现能够在更精确诊断前列腺癌方面发挥重要作用，还能够为开发治愈前列腺癌新的目标药物提供重要信息。随着医学日益个性化，这项本质发现可能会促进开发前列腺癌新的诊断试验和创新治疗。”

HDC公司董事长兼首席执行官 Stephen D. Barnhill, M.D.说：“我坚信，这个新的前列腺癌生物标记发现在针对更准确诊断前列腺癌，以及在治疗此类具有潜在危害癌症过程中确定新的治疗目标提供重要新信息方面，提供了重要的机会。世界卫生组织（WHO）估计，未来25年，全球前列腺癌患者的人数将会增加40%，由此可见这项发现特别重要。HDC公司在开发这项重要新发现预期的商业化应用方面，渴望与诊断及药物合作伙伴开展合作。”

另外，HDC公司此前已经确定并报告了从低恶性级别前列腺癌中区分高级别前列腺癌（Gleason 4级或更高级别）的其他生物标记表达谱。在广泛应用的癌症检查试验显示血液中前列腺特异抗原（PSA）达到一定高水平后，每年有100多万男子接受了前列腺活性组织检查。在这些接受活性组织检查的人中，仅有四分之一的人被发现患有前列腺癌，这就是说，在这些接受活性组织检查的100多万人中约有75万人没有必要进行活性组织检查。通过准确确定身体组织、血液、尿或精液中的生物标记表达谱，准确区分不同级别的癌症，就可以在快速确定哪些男性急需进行更加积极治疗的同时，减少不必要的活性组织检查。

斯坦福大学医学中心（Stanford University Medical Center）全球知名的前列腺癌专家、HDC公司科学团队成员Tom Stamey博士最近在《泌尿外科杂志》发表文章称，由于前列腺特异抗原在临床鉴定大量前列腺癌方面的准确度较低，因此前列腺特异抗原时代已经结束。 Stamey博士认为，需要新的更准确的测试来有效查出此类癌症。每年前列腺特异抗原检查营收估计超过了3.5亿美元，占每年所有癌症血清生物标记检查营收的40%。

HDC公司最近与Pfizer公司（纽约证券交易所：PFE）、Epigenomics公司（法兰克福高标准板块：ECX）以及Bruker Daltonics公司（纳斯达克股票代码：BRKR）签署了许可协议。

位于Savannah的Health Discovery Corporation（场外柜台交易市场代码：HDVY）在模式识别领域具有独一无二的地位。通过其广泛的专利产品组合，以及其公认的科学团队不懈的努力，HDC公司致力于商业化其在基因及蛋白体生物标记发现、医学影像、诊断以及个性化医学领域药物进步方面的专利技术。公司受专利保护的技术还在非医学领域广泛应用，这些领域要求对大量复杂数据库进行处理和分析，其中包括保险业、金融市场、互联网搜索与垃圾邮件以及国土安全领域。

本新闻稿包含1933年《证券法》第27a部分以及1934年《证券交易法》第21E部分界定的前瞻性声明。尽管公司认为此类前瞻性声明所陈述的这些预期非常合理，但是公司并不保证此类预期今后一定能够实现。

联系方式：Health Discovery Corporation

Daniel R. Furth, 912-352-7488

investor@healthdiscoverycorp.com

www.healthdiscoverycorp.com

(BW)(GA-HEALTH-DISCOVERY)(HDVY) Health Discovery Corporation Files for U.S. and Foreign Patent Protection of New Prostate Cancer Biomarker Discovery

New Prostate Cancer Biomarker Expression Signature is Highly Accurate in Identifying Prostate Cancer

SAVANNAH, Ga.--(BUSINESS WIRE)--Feb. 5, 2007--

Health Discovery Corporation ("HDC") (OTCBB: HDVY) announced today that it has filed new patent applications in the United States Patent and Trademark Office and in the U.S. Receiving Office for the Patent Cooperation Treaty for U.S. and foreign patent protection for a newly discovered Prostate Cancer Biomarker Expression Signature which is highly accurate for identifying prostate cancer. This new Prostate Cancer Biomarker Expression Signature was demonstrated to have a very high degree of accuracy as demonstrated by an area under the ROC curve of 94%.

"This new and exciting biomarker discovery could play a significant role in a more accurate diagnosis of prostate cancer as well as providing important information for the development of new drug targets for the successful treatment of prostate cancer," commented Dr. Herbert A. Fritsche, Professor of Laboratory Medicine at the University of Texas M.D. Anderson Cancer Center and Chairman of HDC's Science Team. "As medicine becomes increasingly personalized, discoveries of this nature could facilitate the development of new diagnostic tests and innovative treatments for prostate cancer."

Stephen D. Barnhill, M.D., Chairman & CEO of HDC, said, "I firmly believe that this new Prostate Cancer Biomarker Discovery provides a significant opportunity towards providing a more accurate diagnosis of prostate cancer and important new information for identifying new therapeutic targets in treating this potentially devastating type of cancer. This is especially important since The World Health Organization (WHO) estimates that prostate cancer in men is expected to go up 40% worldwide in the next 25 years. HDC is eager to work with both diagnostic and pharmaceutical partners on developing prospective commercial applications for this important new discovery."

In addition, HDC has previously identified and reported additional Expression Signatures of biomarkers that are capable of distinguishing high-grade prostate cancers (Gleason Grade 4 and higher) from less malignant grades. More than 1 million men a year undergo biopsies of the prostate gland after the widely used cancer-screening test reveals moderately elevated levels of prostate specific antigen (PSA) in the blood. Only one in four of these biopsies find evidence of cancer, meaning that around 750,000 of those million plus biopsies were unnecessary. The ability to clearly distinguish between different cancer grades by accurately identifying biomarker expression signatures in tissue, blood, urine or semen, could reduce the number of unneeded biopsies while quickly identifying those men in urgent need of more aggressive treatment.

According to a recent paper published in the Journal of Urology by Dr. Tom Stamey at Stanford University Medical Center, a world-renowned expert on prostate cancer, and a Member of the HDC Science Team "The Era of PSA is over" because of the low accuracy rate of Prostate Specific Antigen in identifying clinically significant prostate cancer. Dr. Stamey believes that a new more accurate test is needed to effectively detect this type of cancer. PSA sales are estimated at over $350 million annually and represent 40% of all annual cancer serum biomarker revenues.

HDC has recently signed licensing agreements with Pfizer (NYSE: PFE), Epigenomics (Frankfurt, Prime Standard: ECX) and Bruker Daltonics (NASDAQ: BRKR).

Savannah-based Health Discovery Corporation (OTCBB: HDVY) is uniquely positioned in the field of pattern recognition. Through its broad patent portfolio and the efforts of its recognized scientific team, HDC is focused on commercializing its intellectual property in genomic and proteomic biomarker discovery, medical imaging, diagnostics, and pharmaceutical advancements in personalized medicine. The company's patent-protected technology also has significant application in non-medical fields that require manipulation and analysis of large, complex datasets such as insurance, financial markets, Internet search & spam, and homeland security.

This news release contains "forward-looking statements" within the meaning of Section 27a of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.

CONTACT: Health Discovery Corporation

Daniel R. Furth, 912-352-7488

investor@healthdiscoverycorp.com

www.healthdiscoverycorp.com